Botulinum toxin: Dosing and dilution

American Journal of Physical Medicine and Rehabilitation

Volumn 83, Issue 10 SUPPL., 2004, Pages

  Francisco, Gerard E ^a,b,c  

^a UNIVERSITY OF TEXAS   (United States)

^b Institute for Rehabilitation and Research   (United States)

^c NONE   (United States)

Author keywords

Botulinum Toxin; Dosing; Spasticity

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; PHENOL; SPASMOLYTIC AGENT;

AGE; BODY MASS; BRAIN INJURY; CHRONICITY; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; COST OF ILLNESS; DILUTION; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DYSTONIA; HUMAN; MULTIPLE SCLEROSIS; MUSCLE HYPERTONIA; SIDE EFFECT; SPASTICITY; SPINAL CORD INJURY; TREATMENT OUTCOME; XEROSTOMIA;

BOTULINUM TOXINS; BRAIN INJURIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; SPINAL CORD INJURIES;

EID: 4644357369     PISSN: 08949115     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PHM.0000141128.62598.81     Document Type: Conference Paper

References (42)

1. Shaari C, Sanders I: Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve 1993;16:964-9
2. Borodic GE, Ferrante R, Pearce L, et al: Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord 1994;19:31-9
3. Simpson DM, Alexander DN, O'Brien CF, et al: Botulinum toxin type A in the treatment of upper extremity spasticity: A randomized, double-blind, placebo-controlled trial. Neurology 1996;46:1306-10
4. Childers MK, Stacy M, Cooke D, et al: Comparison of two injection techniques using botulinum toxin in spastic hemiplegia. Am J Phys Med Rehabil 1996;75:462-9
5. Bhakta BB, Cozens JA, Bamford JM, et al: Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry 1996;61:30-5
6. Bhakta BB, Cozens AJ, Chamberlain AM, et al: Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: A randomized double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000;69:217-21
7. Bakheit AM, Thilmann AF, Ward AB, et al: A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000;31:2402-6
8. Smith SJ, Ellis E, White S, et al: A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil 2000;14:5-13
9. Russman BS, Tilton A, Gormley ME Jr: Cerebral palsy: A rational approach to a treatment protocol, and the role of botulinum toxin in treatment. Muscle Nerve Suppl 1997;6:S181-93
10. Reiter F, Maura D, Lagalla D, et al: Low-dose botulinum toxin with ankle taping for the treatment of spastic equinovarus foot after stroke. Arch Phys Med Rehabil 1998;79:532-5
11. Hesse S, Lucke D, Malezic M, et al: Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients. J Neurol Neurosurg Psychiatry 1994;57:1321-4
12. Hesse S, Jahnke MT, Luecke D, et al: Short-term electrical stimulation enhances the effectiveness of botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Lett 1995;201:37-40
13. Kirazli Y, On AY, Kismali B, et al: Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke. Am J Phys Med Rehabil 1998;77:510-5
14. Brashear A, Gordon MF, Elovic E, et al: Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002;347:395-400
15. Burbaud P, Wiart L, Dubos JL, et al: A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996;61:265-9
16. Pittock SJ, Moore A, Hardiman O, et al: A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis 2003;15:289-300
17. Hyman N, Barnes M, Bhakta B, et al: Botulinum toxin (Dysport) treatment of hip adductor, spasticity in multiple sclerosis: A prospective, randomized, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 2000;68:707-12
18. Snow BJ, Tsui JK, Bhatt MH, et al: Treatment of spasticity with botulinum toxin: A double-blind study. Ann Neurol 1990;28:512-5
19. Brashear A, McAfee AI, Kuhn ER, et al: Treatment with botulinum toxin type B for upper-limb spasticity. Arch Phys Med Rehabil 2003;84:103-7
20. O'Brien C, Mancini F: Botulinum toxin type B for limb spasticity. Arch Phys Med Rehabil 2001;82:1317
21. Jayasooriya SM, Francisco GE, Healy W: Early experience with the use of botulinum toxin type B for the treatment of upper limb spastic hypertonia. Arch Phys Med Rehabil 2002;83:1677
22. Lagalla G, Danni M, Reiter F, et al: Post-stroke spasticity management with repeated botulinum toxin injections in the upper limb. Am J Phys Med Rehabil 2000;79:377-84
23. Dosing, administration, and a treatment algorithm for use of botulinum toxin type A for adult-onset muscle overactivity in patients with an upper motoneuron lesion: The We Move Spasticity Study Group, in Brin MF (ed): Spasticity: Etiology, Evaluation, Management an the Role of Botulinum Toxin. A We Move Self-Study CME Activity. New York, Wiley, 2002, pp 154-65
24. Foreman W, Francisco GE, Sanchez OA: Safety and efficacy of high dose botulinum toxin type A in managing spastic hypertonia. Arch Phys Med Rehabil 2001;82:1335
25. Turner-Stokes L, Ward A: Botulinum toxin in the management of spasticity in adults. Clin Med 2002;2:128-30
26. Viriyavejakul A, Roongtiwa V, Poungvarin N: Botulinum treatment for post-stroke spasticity: Low dose regime. J Med Assoc Thai 1998;413-22
27. Suputtitada A: Local botulinum toxin type A injections in the treatment of spastic toes. Am J Phys Med Rehabil 2002;81:770-5
28. Eleopra R, Tugnoli V, De Grandis D: The variability in the clinical effect induced by botulinum toxin type A: The role of muscle activity in humans. Mov Disord 1997;12:89-94
29. Kim HS, Hwang JH, Jeong ST, et al: Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis. Dev Med Child Neurol 2003;45:200-6
30. Francisco GE, Boake C, Vaughn A: Botulinum toxin in upper limb spasticity after acquired brain injury: A randomized trial comparing dilution techniques. Am J Phys Med Rehabil 2002;81:355-63
31. Gracies JM, Weisz DJ, Yang BY, et al: Impact of botulinum toxin type A (BTX-A) dilution and endplate targeting technique in upper limb spasticity. Ann Neurol 2002;52(suppl 1):S87
32. Pavesi G, Brianti R, Medici D, et al: Botulinum toxin type A in the treatment of upper limb spasticity among patients with traumatic brain injury. J Neurol Neurosurg Psychiatry 1998;64:419-20
33. Wang HC, Hsieh LF, Chi WC, et al: Effects of intramuscular botulinum toxin injection on upper limb spasticity in stroke patients. Am J Phys Med Rehabil 2002;81:272-8
34. Panizza M, Castagna M, di Summa A, et al: Functional and clinical changes in upper limb spastic patients treated with botulinum toxin (BTX). Funct Neurol 2000;15:147-55
35. Girlanda P, Quartarone A, Sinicropi S, et al: Botulinum toxin in upper limb spasticity: Study of reciprocal inhibition between forearm muscles. NeuroReport 1997;8:3039-44
36. Sampaio C, Ferreira J, Pinto AA, et al: Botulinum toxin type A for the treatment of arm and hand spasticity in stroke patients. Clin Rehabil 1997;11:3-7
37. Palmer D, Horn LJ, Harmon R: Botulinum toxin treatment of lumbrical spasticity: A brief report. Am J Phys Med Rehabil 1998;77:348-50
38. Yelnik A, Colle FM, Bonan I, et al: Disabling overactivity of the extensor hallucis longus after stroke: Clinical expression and efficacy of botulinum toxin type A. Arch Phys Med Rehabil 2003;84:147-9
39. Yelnik AP, Colle FM, Bonan IV: Treatment of pain and limited movement of the shoulder in hemiplegic patients with botulinum toxin A in the subscapularis muscle. Eur Neurol 2003;50:91-3
40. Summary of product characteristics: Dysport. Dublin, Ipsen Pharmaceuticals. Available at: www.ipsen.ie. Accessed November 13, 2003
41. Johnson CA, Wood DE, Swain DI, et al: A pilot study to investigate the combined use of botulinum neurotoxin type A and functional electrical stimulation, with physiotherapy, in the treatment of spastic dropped foot in subacute stroke. Artif Organs 2002;26:263-6
42. Hesse S, Reiter F, Konrad M, et al: Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: A randomized, double-blind, placebo-controlled trial. Clin Rehabil 1998;12:381-8